---
document_datetime: 2025-05-06 11:36:59
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mavenclad-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mavenclad-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.0510092
conversion_datetime: 2025-12-29 20:54:47.478322
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mavenclad

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10634 /202407  | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                     | 27/02/2025                          | 23/04/2025                                  | SmPC                             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10634/202407. |
| II/0032              | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/07/2024                          | 27/09/2024                                  | SmPC and PL                      |                                                                                                                                            |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0033/G           | This was an application for a group of variations.                            | 22/04/2024   | n/a   |                                   |
|---------------------|-------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10634 /202307 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis) | 08/02/2024   | n/a   | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0027   | Update of sections 4.5 and 4.6 of the SmPC in order to add information regarding the use of mavenclad with oral contraceptives based on the final study results from the drug-drug interaction study (MS 700568-0031). This is a randomized, double-blind, 2-period, 2-sequence, crossover Phase I study with a 1-month run-in period to examine the effect of cladribine tablets on the pharmacokinetics of a monophasic oral contraceptive containing ethinyl estradiol and levonorgestrel (microgynon) in pre- menopausal women with Relapsing Multiple Sclerosis (RMS). The Annex II and Package Leaflet are updated accordingly. The RMP was updated to version 2.2, with a DLP 07 July 2023. In addition, the MAH took the opportunity implement editorial changes to sections 4.2 and 4.4 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 30/11/2023   | 27/09/2024   | SmPC, Annex II and PL   | SmPC new text Sections 4.5 and 4.6 of the SmPC have been updated to reflect the results of the DDI study. Co-administration of cladribine with oral hormonal contraceptives (ethinylestradiol and levonorgestrel) showed no clinically relevant pharmacokinetic interaction with cladribine. Therefore, concomitant use of cladribine is not expected to decrease the efficacy of hormonal contraceptives. The recommendation to add a barrier method during cladribine treatment has been removed. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0031   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/11/2023   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0030   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 08/11/2023   | n/a          |                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IAIN/0029/G         | This was an application for a group of variations.                                                                                                                                               | 04/10/2023   | 27/09/2024   | Annex II and PL     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------|-----------------------------------|
| PSUSA/10634 /202207 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                                                                                                    | 09/02/2023   | n/a          |                     | PRAC Recommendation - maintenance |
| IAIN/0026           | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority        | 15/12/2022   | n/a          |                     |                                   |
| IAIN/0025           | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer          | 18/10/2022   | n/a          |                     |                                   |
| IA/0023             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 03/05/2022   | n/a          |                     |                                   |
| R/0022              | Renewal of the marketing authorisation.                                                                                                                                                          | 24/02/2022   | 25/04/2022   | SmPC, Labelling and |                                   |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                         |            |            | PL                    |                                                                                                                                                                                                                                                                                                                      |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                       | 13/01/2022 | 04/03/2022 | SmPC, Annex II and PL |                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10634 /202107 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                                                                                                                                                                                                                                                                           | 10/02/2022 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                    |
| II/0016             | Update of section 4.8 of the SmPC in order to add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency 'common' based on a review of cumulative clinical and post-marketing data. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 02/12/2021 | 04/03/2022 | SmPC and PL           | Hypersensitivity is added to the list of adverse drug reactions with frequency 'common'. It has been specified that hypersensitivity events included pruritus, urticaria, rash and rare cases of angio-oedema. PL updated accordingly. For more information, please refer to the Summary of Product Characteristics. |
| II/0015             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                          | 30/09/2021 | n/a        |                       |                                                                                                                                                                                                                                                                                                                      |
| IB/0019/G           | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                               | 24/02/2021 | 04/03/2022 | SmPC                  |                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                     | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0017             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/02/2021 | n/a |                                   |
| PSUSA/10634 /202007 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/02/2021 | n/a | PRAC Recommendation - maintenance |
| IAIN/0018           | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                                                                                                                                                                                                                                          | 25/01/2021 | n/a |                                   |
| IB/0013/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting | 05/06/2020 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |            |                                  |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| PSUSA/10634 /201907 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                                                                                                                                                                                                                                                         | 16/01/2020 | n/a        |                                  | PRAC Recommendation - maintenance |
| IB/0012             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                        | 07/01/2020 | 09/12/2020 | SmPC, Annex II, Labelling and PL |                                   |
| IB/0011             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                          | 16/12/2019 | n/a        |                                  |                                   |
| II/0009             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                         | 28/11/2019 | n/a        |                                  |                                   |
| IB/0008/G           | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-                                                     | 31/10/2019 | n/a        |                                  |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                     | release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch   |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10634 /201901 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/07/2019 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0007             | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/05/2019   | n/a        |                        |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| PSUSA/10634 /201807 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/01/2019   | n/a        |                        | PRAC Recommendation - maintenance |
| PSUSA/10634 /201801 | Periodic Safety Update EU Single assessment - cladribine (multiple sclerosis)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06/09/2018   | n/a        |                        | PRAC Recommendation - maintenance |
| T/0004              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/06/2018   | 09/07/2018 | SmPC, Labelling and PL |                                   |
| IB/0002/G           | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.z - Change in batch size (including batch size ranges) of AS or intermediate - Other variation B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition or replacement of an in-process test as a result of a safety or quality issue | 15/01/2018   | n/a        |                        |                                   |
| IA/0001             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/12/2017   | 09/07/2018 | SmPC                   |                                   |